259 related articles for article (PubMed ID: 33779349)
1. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
Kofler K; Strölin A; Geiger V; Kofler L
J Cutan Med Surg; 2021 Sep; 25(5):504-510. PubMed ID: 33779349
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
[TBL] [Abstract][Full Text] [Related]
3. Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: seven cases and a literature review.
Kim EJ; Yoon SY; Park HS; Yoon HS; Cho S
Dermatol Ther; 2015; 28(5):287-90. PubMed ID: 25845419
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: five cases and a literature review.
Bounfour T; Bouaziz JD; Bézier M; Petit A; Viguier M; Rybojad M; Bagot M
Int J Dermatol; 2013 Sep; 52(9):1135-9. PubMed ID: 23488633
[TBL] [Abstract][Full Text] [Related]
5. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy.
Bhatt DM; Bhamburkar S; Madke B; Jangid SD; Khan A
Cureus; 2023 Dec; 15(12):e50053. PubMed ID: 38186477
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intravenous immunoglobulin for treating refractory livedoid vasculopathy: a systematic review.
Gao Y; Jin H
Ther Adv Chronic Dis; 2022; 13():20406223221097331. PubMed ID: 35634570
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series.
Ozden MG; Ozdemir H; Şenturk N
Dermatol Ther; 2020 Mar; 33(2):e13229. PubMed ID: 31965687
[TBL] [Abstract][Full Text] [Related]
9. Response of livedoid vasculitis to intravenous immunoglobulin.
Ravat FE; Evans AV; Russell-Jones R
Br J Dermatol; 2002 Jul; 147(1):166-9. PubMed ID: 12100203
[TBL] [Abstract][Full Text] [Related]
10. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients.
Kreuter A; Gambichler T; Breuckmann F; Bechara FG; Rotterdam S; Stücker M; Altmeyer P
J Am Acad Dermatol; 2004 Oct; 51(4):574-9. PubMed ID: 15389193
[TBL] [Abstract][Full Text] [Related]
11. Clinical, Laboratory, Histopathological and Therapeutic Profile of Livedoid Vasculopathy: A Case Series of 17 Patients.
Shah SR; Vyas HR; Doshi YJ; Shah BJ
Indian Dermatol Online J; 2022; 13(6):771-774. PubMed ID: 36386750
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Rivaroxaban and Immunoglobulin Therapy in the Treatment of Livedoid Vasculopathy: A Systematic Review.
Ramphall S; Rijal S; Prakash V; Ekladios H; Mulayamkuzhiyil Saju J; Mandal N; Kham NI; Shahid R; Naik SS; Venugopal S
Cureus; 2022 Aug; 14(8):e28485. PubMed ID: 36051980
[TBL] [Abstract][Full Text] [Related]
13. Livedoid vasculopathy - A diagnostic and therapeutic challenge.
Burg MR; Mitschang C; Goerge T; Schneider SW
Front Med (Lausanne); 2022; 9():1012178. PubMed ID: 36262273
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis.
Gao Y; Jin H
J Dermatolog Treat; 2022 Feb; 33(1):178-183. PubMed ID: 32116074
[TBL] [Abstract][Full Text] [Related]
15. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.
Gardette E; Moguelet P; Bouaziz JD; Lipsker D; Dereure O; Le Pelletier F; Lok C; Maisonobe T; Bessis D; Conard J; Francès C; Barete S
Acta Derm Venereol; 2018 Oct; 98(9):842-847. PubMed ID: 29738044
[TBL] [Abstract][Full Text] [Related]
16. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
[TBL] [Abstract][Full Text] [Related]
17. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.
Camara I; Sciascia S; Simoes J; Pazzola G; Salas V; Karim Y; Roccatello D; Cuadrado MJ
Clin Exp Rheumatol; 2014; 32(1):41-7. PubMed ID: 24029366
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin-A: A novel treatment for livedoid vasculopathy.
Crotty AM; Eubanks BN; Katana VG; Wright KT
JAAD Case Rep; 2022 Nov; 29():27-29. PubMed ID: 36186404
[No Abstract] [Full Text] [Related]
19. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.
Weishaupt C; Strölin A; Kahle B; Kreuter A; Schneider SW; Gerss J; Eveslage M; Drabik A; Goerge T
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1784-1791. PubMed ID: 31009111
[TBL] [Abstract][Full Text] [Related]
20. Punch grafting for the treatment of ulcerated atrophie blanche.
Orbea Sopeña A; Conde Montero E
Phlebology; 2023 Dec; 38(10):695-697. PubMed ID: 37624370
[No Abstract] [Full Text] [Related]
[Next] [New Search]
